These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 21424459)

  • 1. Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study.
    Eifler AC; Thaxton CS
    Methods Mol Biol; 2011; 726():325-38. PubMed ID: 21424459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticle therapeutics: a personal perspective.
    McNeil SE
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2009; 1(3):264-71. PubMed ID: 20049796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review.
    Tyner K; Sadrieh N
    Methods Mol Biol; 2011; 697():17-31. PubMed ID: 21116951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer nanotherapeutics in clinical trials.
    Lytton-Jean AK; Kauffman KJ; Kaczmarek JC; Langer R
    Cancer Treat Res; 2015; 166():293-322. PubMed ID: 25895874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic.
    Davis ME
    Mol Pharm; 2009; 6(3):659-68. PubMed ID: 19267452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colloidal gold: a novel nanoparticle for targeted cancer therapeutics.
    Powell AC; Paciotti GF; Libutti SK
    Methods Mol Biol; 2010; 624():375-84. PubMed ID: 20217609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile of RNAi nanomedicines.
    Barros SA; Gollob JA
    Adv Drug Deliv Rev; 2012 Dec; 64(15):1730-7. PubMed ID: 22732527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma.
    Hu-Lieskovan S; Heidel JD; Bartlett DW; Davis ME; Triche TJ
    Cancer Res; 2005 Oct; 65(19):8984-92. PubMed ID: 16204072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances.
    Li SD; Huang L
    Curr Opin Investig Drugs; 2008 Dec; 9(12):1317-23. PubMed ID: 19037838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticle formulations in pulmonary drug delivery.
    Bailey MM; Berkland CJ
    Med Res Rev; 2009 Jan; 29(1):196-212. PubMed ID: 18958847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic targeting in the silent era: advances in non-viral siRNA delivery.
    Guo J; Fisher KA; Darcy R; Cryan JF; O'Driscoll C
    Mol Biosyst; 2010 Jul; 6(7):1143-61. PubMed ID: 20431817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanotheranostics and image-guided drug delivery: current concepts and future directions.
    Lammers T; Kiessling F; Hennink WE; Storm G
    Mol Pharm; 2010 Dec; 7(6):1899-912. PubMed ID: 20822168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is special FDA regulation of nanomedicine needed? A conversation with Norris E. Alderson. Interview by Barbara J Culliton.
    Alderson NE
    Health Aff (Millwood); 2008; 27(4):w315-7. PubMed ID: 18559355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unique benefits of nanotechnology to drug delivery and diagnostics.
    McNeil SE
    Methods Mol Biol; 2011; 697():3-8. PubMed ID: 21116949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticle therapeutics: an emerging treatment modality for cancer.
    Davis ME; Chen ZG; Shin DM
    Nat Rev Drug Discov; 2008 Sep; 7(9):771-82. PubMed ID: 18758474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.